

-120-

What is claimed is:

1. A method of generating antigen specific allospecific human suppressor CD8+CD28- T cells which comprises:

5

a) obtaining peripheral blood T cells from a subject;

10

b) stimulating by multiple priming a T cell line from the T cells obtained in step (a) with allogeneic antigen presenting cells (APCs), said APCs expressing an MHC class I antigen recognized by the primed T cell line and an MHC class II antigen recognized by CD4+ T helper cells from said primed T cell line;

15

c) isolating primed CD8+ T cells and CD4+ T helper cells from the T cell line stimulated in step (b);

20

d) isolating primed CD8+CD28- T cells from the isolated primed CD8+ T cells of step (c);  
25  
e) detecting suppression by the primed CD8+CD28- T cells isolated in step (d) of interaction between the CD4+ T helper cells isolated in step (c) and allogeneic antigen presenting cells (APCs) expressing the same MHC class I antigen and the same MHC class II antigen expressed by the APCs used to stimulate the T cell line of step (b), thereby identifying antigen specific allospecific human suppressor CD8+CD28- T cells; and

30

f) expanding in culture the antigen specific allospecific human suppressor CD8+CD28- T cells identified in step (e), thereby generating the antigen specific allospecific human suppressor CD8+CD28- T cells.  
35

-121-

2.. The method of claim 1 wherein the MHC class I antigen is an HLA-A or HLA-B antigen expressed by the APC used for priming in step (b).

5 3. The method of claim 1 wherein the MHC class II antigen is an HLA-DR, HLA-DQ or HLA-DP antigen.

10 4. Antigen specific allospecific human suppressor CD8+ CD28+ T cells produced by the method of claim 1.

15 5. A method of generating xenospecific human suppressor CD8+CD28- T cells which comprises:

15 a) obtaining peripheral blood T cells from a human subject;

20 b) stimulating by multiple priming a human T cell line from the T cells obtained in step (a) with a xenogeneic antigen presenting cells (APCs), said APCs expressing a xenogeneic MHC class I antigen and a xenogeneic MHC class II antigen;

25 c) isolating primed human CD8+ T cells and human\_CD4+ T helper cells from the T cell line stimulated in step (b);

30 d) isolating primed human CD8+CD28- T cells from the isolated primed human CD8+ T cells of step (c);

35 e) detecting suppression by the primed human CD8+CD28- T cells isolated in step (d) of interaction between the human CD4+ T helper cells isolated in step (c) and xenogeneic antigen presenting cells (APCs) expressing the same xenogeneic MHC class I antigen and xenogeneic MHC class II antigen expressed by the xenogeneic APCs used to stimulate the human T cell line of step (b), thereby identifying xenospecific human suppressor

-122-

CD8+CD28- T cells; and

5 f) expanding the xenospecific human suppressor CD8+CD28- T cells identified in step (e), thereby generating the xenospecific human suppressor CD8+CD28- T cells.

10 6. The method of claim 5 wherein the xenospecific mammalian antigen presenting cells (APCs) are selected from pig or primate APCs.

15 7. The method of claim 5 wherein the xenogeneic MHC class I antigen is selected from the group consisting of swine histocompatibility leukocyte antigen (SLA) class-I and MHC class II antigen is selected from the group consisting of swine histocompatibility leukocyte antigen (SLA) class-II.

20 8. Xenospecific human suppressor CD8+ CD28+ T cells produced by the method of claim 5.

25 9. A method of generating allopeptide antigen specific human suppressor CD8+CD28- T cells which comprises:

a) obtaining peripheral blood T cells from a subject;

30 b) stimulating by multiple priming a T cell line from the T cells obtained in step (a) with autologous antigen presenting cells (APCs) pulsed with an allopeptide, said allopeptide comprising an amino acid sequence comprising both MHC class I and MHC class II amino acid sequences wherein the amino acid sequences are binding sequences and are recognized by the primed T cell line;

35 c) isolating primed CD8+ T cells and CD4+ T helper cells from the T cell line stimulated in step (b);

-123-

d) isolating primed CD8+CD28- T cells from the isolated primed CD8+ T cells of step (c);

5 e) detecting suppression by the primed CD8+CD28- T cells isolated in step (d) of interaction between the CD4+ T helper cells isolated in step (c) and autologous antigen presenting cells (APCs) expressing the same MHC class I and MHC class II binding motifs as expressed by the APCs used to stimulate the T cell line of step (b), thereby identifying allopeptide antigen specific human suppressor CD8+CD28- T cells; and

10 f) expanding the allopeptide antigen specific human suppressor CD8+CD28- T cells identified in step (e), thereby generating the allopeptide antigen specific human suppressor CD8+CD28- T cells.

15 10. The method of claim 9 wherein the allopeptide is selected from the group consisting of a peptide antigen, a whole protein antigen, tat-DR4 peptide or a peptide comprising an amino acid sequence of a hypervariable region of HLA-DR B1.

20 11. Antigen specific human suppressor CD8+CD28- T cells produced by the method of claim 9.

25 12. A method of determining whether a level of immunosupresant therapy given to a subject undergoing the level immunosuppression therapy requires a reduction which comprises:

30 a) obtaining a blood sample from the subject; and  
35 b) determining the presence of T suppressor cells present in the sample,

-124-

the presence of T suppressor cells indicating that the subject requires the reduction of immunosuppressant therapy.

5        13. The method of claim 12 wherein the T suppressor cells are suppressor CD8+CD28- T cells.

10        14. A method of reducing the risk of rejection of an allograft in a subject undergoing immunosuppression therapy which comprises:

- 15              a) obtaining a blood sample from the subject;  
                  b) removing T suppressor cells from the blood sample;  
                  c) expanding the T suppressor cells of step (b); and  
                  d) reintroducing the expanded T suppressor cells of step (b) into the subject.

20        15. The method of claim 14 wherein the T suppressor cells are suppressor CD8+CD28- T cells.

25        16. A method of reducing the level of rejection of an allograft in a subject undergoing immunosuppression therapy which comprises administering to the subject the T suppressor cells produced by the method of claim 1, thereby preventing rejection of the tissue or organ transplant in the subject.

30        17. A method of reducing the level of rejection of an allograft in a subject undergoing immunosuppression therapy which comprises administering to the subject the T suppressor cells produced by the method of claim 9, thereby preventing rejection of the tissue or organ transplant in the subject.

35        18. A method of preventing rejection of an allograft in a subject which comprises:

- a) obtaining a blood sample from the subject;

-125-

- b) removing T suppressor cells from the blood sample;
- c) expanding the T suppressor cells of step (b); and
- 5 d) reintroducing the expanded T suppressor cells of step (b) into the subject,

thereby preventing the rejection of the allograft in the subject.

*Rule*

*1.12b 18*

10 18. A method of preventing rejection of an allograft in a subject which comprises administering the T suppressor cells produced by the method of claim 1 to the subject, thereby preventing rejection of the allograft in the subject.

15

*20 19*

19. A method of preventing rejection of an allograft in a subject which comprises administering the T suppressor cells produced by the method of claim 9 to the subject, thereby preventing rejection of the allograft in the subject.

20

*21 20*

20. A method of preventing rejection of a xenograft in a subject which comprises:

25

a) obtaining a blood sample from the subject;

30

b) removing T suppressor cells from the blood sample;

35

c) expanding the T suppressor cells of step (b); and

d) reintroducing the expanded T suppressor cells of step (b) into the subject,

thereby preventing the rejection of the xenograft in the subject.

35

*22 21*

21. The method of claim 20 wherein the T suppressor cells are suppressor CD8+CD28- T cells.

*Rule 1.126*

-126-

23 *22.* A method of preventing rejection of a xenograft in a subject which comprises administering the T suppressor cells produced by the method of claim 5 to the subject, thereby preventing rejection of the xenograft in the subject.

5

24 *23.* A method of preventing autoimmune disease in a subject which comprises:

10

a) obtaining a blood sample from the subject;

b) removing T suppressor cells from the blood sample;

c) expanding the T suppressor cells of step (b); and

15

d) reintroducing the expanded T suppressor cells of step (b) into the subject,

thereby preventing autoimmune disease in the subject.

20

25 *24.* The method of claim 23 wherein the T suppressor cells are suppressor CD8+CD28- T cells.

25

26 *25.* A method of preventing autoimmune disease in a subject which comprises administering the T suppressor cells produced by the method of claim 1 to the subject, thereby preventing autoimmune disease in the subject.

30

27 *26.* A method of preventing autoimmune disease in a subject which comprises administering the T suppressor cells produced by the method of claim 9 to the subject, thereby preventing autoimmune disease in the subject.

35

28 *27.* A vaccine comprising allospecific T suppressor cells stimulated by APCs expressing an MHC class I antigen and an MHC class II antigen which T suppressor cells suppress an interaction between CD4+ T helper cells and allogeneic antigen presenting cells (APCs) expressing the same MHC class I antigen and the same MHC class II antigen expressed by the

-127-

APCs used to stimulate the allospecific T suppressor cells.

R461.126

29 28. The vaccine of claim 27 wherein the APCs are allogeneic  
APCs said APCs expressing an MHC class I antigen recognized  
by the T suppressor cells and an MHC class II antigen  
recognized by allogeneic CD4+ T helper cells.

30 29.

The vaccine of claim 27 wherein the APCs are APCs pulsed  
with an allopeptide, said allopeptide comprising an amino  
acid sequence having both MHC class I and MHC class II  
binding motifs wherein both motifs are recognized by the  
stimulated T suppressor cells.

31 30.

The vaccine of claim 27 wherein the T suppressor cells  
are suppressor CD8+CD28- T cells.

32 31.

A vaccine comprising xenospecific T suppressor cells  
stimulated by APCs expressing a xenospecific MHC class I  
antigen and a xenogeneic MHC class II antigen which  
xenogeneic T suppressor cells suppress an interaction between  
CD4+ T helper cells and xenogeneic antigen presenting cells  
(APCs) expressing the same xenogeneic MHC class I antigen and  
xenogeneic MHC class II antigen expressed by the APCs used  
to stimulate the xenospecific T suppressor cells.

25

33 32.

The vaccine of claim 31 wherein the T suppressor cells  
are suppressor CD8+CD28- T cells.

34 33.

A method of inducing anergic T helper cells which  
comprises:

30

- a) incubating antigen presenting cells (APC) with  
allospecific T suppressor cells (Ts);
- b) overexpressing in the APC mRNA which encodes at least  
one monocyte inhibitory receptor (MIR), in a mixture of  
cells comprising the APCs from step (a), wherein  
overexpression of MIR transmits negative inhibitory signals  
to recruit an inhibitory signaling molecule, tyrosine

35

-128-

phosphatase SHP-1 such that the APC are rendered tolerogenic; and

c) incubating the APCs from step (b) with T helper cells (Th) to induce Th anergy.

5

*Rule 1.126*  
35 ~~34.~~ The method of claim 33, wherein the monocyte inhibitory receptor (MIR) is selected from the group consisting of ILT4 (MIR-10), ILT2 (MIR7), and ILT3.

10

36 ~~35.~~ The method of claim 33, wherein the Ts are allospecific human suppressor CD8+CD28- T cells.

11

37 ~~36.~~ The method of claim 33, wherein the Ts are xenospecific human suppressor CD8+CD28- T cells.

12

38 ~~37.~~ The method of claim 33, wherein the Ts allopeptide are antigen specific human suppressor CD8+CD28- T cells.

13

39 ~~38.~~ A method of generating a tolerogenic antigen presenting cell (APC) which comprises:

14

a) contacting the APC with Ts; and  
b) overexpressing mRNA which encodes an MIR in the APC, thereby generating a tolerogenic antigen presenting cell (APC).

15

40 ~~39.~~ The method of claim 38, wherein the monocyte inhibitory receptor (MIR) is selected from the group consisting of ILT4 (MIR-10), ILT2 (MIR7), and ILT3.

16

41 ~~40.~~ The method of claim 38, wherein the Ts are antigen specific allospecific human suppressor CD8+CD28- T cells.

17

42 ~~41.~~ The method of claim 38, wherein the Ts are xenospecific human suppressor CD8+CD28- T cells.

18

43 ~~42.~~ The method of claim 38, wherein the Ts are allopeptide antigen specific human suppressor CD8+CD28- T cells.

-129-

*Rule 1.126*

44 43. A method of reducing the level of rejection of an allograft tissue or organ in a subject who is a transplant recipient of the allograft tissue or organ which comprises administering to the subject tolerogenic antigen presenting cells (APC) which overexpress monocyte inhibitory receptor (MIR), wherein the APC have been incubated with Ts prior to overexpression of MIR, thereby inducing Th anergy so as to prevent rejection of the tissue or organ allograft in the subject.

10

45 44. The method of claim 43, wherein the monocyte inhibitory receptor (MIR) is selected from the group consisting of ILT4 (MIR-10), ILT2 (MIR7), and ILT3.

15

46 45. The method of claim 43, wherein the Ts are allospecific human suppressor CD8+CD28- T cells.

47 46. The method of claim 43, wherein the Ts are xenospecific human suppressor CD8+CD28- T cells.

20

48 47. The method of claim 43, wherein the Ts are allopeptide antigen specific human suppressor CD8+CD28- T cells.

25

49 48. A method of suppressing an autoimmune disease in a subject which comprises:

- a) contacting antigen presenting cells (APC) of the subject with T suppressor cells (Ts) specific for the antigen which induces the autoimmune disease; and
- b) administering to the subject the APC of step(a), thereby inducing tolerance to the antigen so as to suppress the autoimmune disease in the subject.

30

50 49. The method of claim 48, wherein the monocyte inhibitory receptor (MIR) is selected from the group consisting of ILT4 (MIR-10), ILT2 (MIR7), and ILT3.

35

-130-

Rule 51 ~~50~~. The method of claim 48, wherein the Ts are allospecific  
1.126 human suppressor CD8+CD28- T cells.

52 ~~51~~. The method of claim 48, wherein the Ts are xenospecific  
5 human suppressor CD8+CD28- T cells.

53 ~~52~~. The method of claim 48, wherein the Ts are allopeptide  
antigen specific human suppressor CD8+CD28- T cells.

54 ~~53~~. A method of suppressing an autoimmune disease in a  
subject which comprises:

- a) overexpressing monocyte inhibitory receptor (MIR) in antigen presenting cells (APC) of the subject, which APC present the antigen which induces the autoimmune disease and are genetically engineered to overexpress MIR; and
- b) administering to the subject the APC of step(a), thereby inducing tolerance to the antigen so as to suppress the autoimmune disease in the subject.

55 ~~54~~. The method of claim 53, wherein the monocyte inhibitory receptor (MIR) is selected from the group consisting of ILT4 (MIR-10), ILT2 (MIR7), and ILT3.

25 56 ~~55~~. A method of inducing tolerance to an allograft tissue or organ in a subject which comprises administering to the subject tolerogenic antigen presenting cells (APC) which overexpress monocyte inhibitory receptor (MIR), thereby inducing tolerance to the allograft in the subject.

30

35

-131-

Rule  
1.126

57<sup>56</sup>. A method of inducing tolerance to a xenograft tissue or organ in a subject which comprises administering to the subject tolerogenic antigen presenting cells (APC) which overexpress monocyte inhibitory receptor (MIR), thereby inducing tolerance to the xenograft in the subject.

5

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000